Human bone marrow-derived mesenchymal stem cells (BM-hMSCs) are nonhematopoietic stem cells that have the potential to differentiate into adipocytes, osteocytes and chondrocytes. Because of its propensity to migrate to the sites of injury and the ability to expand them rapidly, BM-hMSCs have been exploited as potential gene transfer vehicles to deliver therapeutic genes. Herein, we evaluated the feasibility of employing herpes simplex virus type I (HSV-1) amplicon viral vector as a gene delivery vector to BM-hMSCs. High transduction efficiencies were consistently observed in different isolates of BM-hMSCs following infection with HSV-1 amplicon viral vectors. Furthermore, we demonstrated that transduction with HSV-1 amplicon viral vector did not alter the intrinsic properties of the BM-hMSCs. The morphology and cellular proliferation of the transduced BM-hMSCs were not altered. Chromosomal stability, as confirmed by karyotyping and soft agar colony assays, of the transduced BM-hMSCs was not affected. Similarly, transduction with HSV-1 amplicon viral vectors has no effect on the pluripotent differentiation potential and the tumor tropism of BM-hMSCs. Taken together, these results demonstrated that BM-hMSCs could be transduced efficiently by HSV-1 amplicon viral vector in an 'inert' manner and thus enable strategies to express potential therapeutic genes in BM-hMSCs.
Introduction
Stem cell therapy has rapidly emerged as a promising approach to deliver therapeutic genes for injury repair and cancer therapies. Human bone marrow-derived mesenchymal stem cells (BM-hMSCs) have been demonstrated to differentiate in vitro [1] [2] [3] [4] [5] [6] [7] and in vivo into neurallike cells following transplantation into mouse brain. 8, 9 Currently, BM-hMSCs are used for preclinical treatment in myocardial infarction 10, 11 and neuronal injury. 12 Ongoing clinical trials based on the use of MSCs include the treatment for graft-vs-host disease, autologous MSCs transplant for peridontitis, severe chronic myocardial ischemia and the treatment of distal fibia fractures. 13 Besides being easily obtainable, BM-hMSCs could be easily expandable and is of significant clinical interest as it could be employed in an autologous setting.
BM-hMSCs could potentially be employed as delivery vehicles following the incorporation of therapeutic genes for specific human disease. [14] [15] [16] This approach would obviate the need for long-term selection of stable clones that may potentially lead to senescence, lost of multilineage differentiation capacity and lost of migratory potential of BM-hMSCs. The development of an efficient gene delivery vector to achieve high expression of therapeutic genes in BM-hMSCs is needed. Different approaches have been employed for delivery of transgene into BM-hMSCs. Nucleofection is a technique whereby the plasmid DNA is transfected directly into the cell nucleus through electrical pulse. Aslan et al. 17 showed that human bone morphogenetic protein-2 or 9-nucleofected BM-hMSCs were able to induce bone formation 4 weeks after in vivo engraftment. However, the low level of gene expression signifies the need for long-term selection of stable clones. Recombinant adenoviruses (Ads) are most commonly used for gene delivery because they can be produced to high titers and can transduce both dividing and nondividing cells. However, they have low and short-term gene expression level, thus required high multiplicity of infection (MOI) to achieve a therapeutic efficiency. 15 Moreover, Ad vector is known to induce severe immunological reactions. 18 On the other hand, the baculovirus system has been shown to confer relatively high transduction efficiency in BM-hMSCs albeit shortterm gene expression. 19, 20 The human immunodeficiency virus (HIV)-based lentiviral vectors are currently promising tool for gene delivery to stem cells because they are able to stably transduced both proliferating and nonproliferating cells. 21 However, lentiviral integration into host-cell chromosomes potentially leading to insertional mutagenesis is a major concern in the application of lentiviral vector for cancer therapy. It has been shown that transcriptionally active genes are preferentially targeted for lentiviral integration. 22 Themis et al. 23 further showed that gene delivery to fetal and neonatal mice led to high incidence of lentiviral vector-associated tumorigenesis. In addition, transgene expression mediated by lentiviral vectors could be rapidly silenced when transduced into mouse embryonic carcinoma cells, possibly through CpG hypermethylation of the transgene promoter and modifications of the chromatin. 24 These observations warrant the design of alternative improved gene delivery viral vectors to ensure long-term safety and stable transgene expression.
Herpes simplex virus-1 (HSV-1) vectors are attractive vehicles for gene therapy due to their broad host range, large transgene capacity and their ability to transduce both nondividing and dividing cells. HSV-1 vectors have been widely used for gene delivery, especially to the brain due to its neurotrophic properties. 25 The recombinant HSV-1, either replication conditional or defective, contains the full viral genome with mutations in one or more viral genes. The replication-conditional recombinant HSV-1 viral vectors have been used to efficiently transduce neural precursor cells. 26 The HSV-1 amplicon vectors are plasmid-based vectors that consist of sequences from the HSV-1 packaging signal (pac) and the HSV-1 origin of replication (together about 1 kb). These viral elements are needed for the amplicon plasmid vectors to be packaged into replication defective infectious virions in the presence of HSV helper functions. 27, 28 HSV-1 amplicon viral vectors excel in their capacity to package large transgene insert of up to 150 kb, 13, [29] [30] [31] which is in contrast to the 8 kb allowable insert size of lentiviral vector. The large transgene capacity of HSV-1 amplicon viral vectors enabled for the insertion of therapeutic genes such as dystrophin (full-length cDNA of 17.3 kb) and frataxin (encoded by the 135 kb gene FRDA) for the treatment of Duchenne's muscular dystrophy 32 and Friedreich's ataxia, 33 respectively, which is not possible with other vector system. Furthermore, the large insert capacity of the HSV-1 amplicon viral vectors also allow for the incorporation of multiple transgene cassettes or additional regulatory sequences required for controlling the transgene expression. In contrast to the recombinant HSV-1, which contains most of the viral elements, the HSV-1 amplicon viral vectors are nonimmunogenic and nontoxic when packaged using the helper virus-free packaging system. [34] [35] [36] HSV-1 amplicon viral vectors have been used to efficiently transduced hepatocytes and primary hepatocellular carcinoma cells, 36, 37 embryonic stem cells and their derivatives 38, 39 and neural progenitor cells. 40 Therapeutic treatment of neural progenitor cells with the proapoptotic protein, tumor necrosis factor-related apoptosis-inducing ligand, conferred therapeutic gene efficacy in glioma treatment. 40 However, the application of HSV-1 amplicon viral vectors for the transduction of BM-hMSCs has not been reported. In this study, we evaluated the efficiency of gene transfer in BM-hMSCs using HSV-1 amplicon as a gene delivery vehicle for BM-hMSCs.
Materials and methods

Isolation and characterization of human mesenchymal stem cells
This study has been approved by the Institutional Review Board of the Singapore General Hospital and National Cancer Centre, Singapore. Bone marrow cells were isolated from femoral head after informed consent from patients undergoing hip-replacement surgery. The marrow were mixed with culture medium (Dulbecco's modified Eagle's medium (DMEM)/F12 with 10% fetal bovine serum (FBS; Invitrogen, Grand Island, NY) and ascorbic acid (Sigma-Aldrich Corp., St Louis, MO)) and subjected to Ficoll-Hypaque density gradient centrifugation. The collected cells were plated in tissue culture flasks without further interference for 2-3 days. The culture was depleted of hematopoietic cells by successive changes of culture medium. A confluent monolayer culture with cells of spindle/fibroblastic morphology was observed 7 days following initial plating. BM-hMSCs is characterized by the presence of the defined cellular markers CD44, CD90 and CD105.
The multipotentiality of BM-hMSCs was assessed by culturing the cells in defined induction medium to induce differentiation into osteogenic and adipogenic lineage. To induce osteoblasts formation, subconfluent BM-hMSCs from passage 3-4 were induced in 10 À8 M dexamethasone, 50 mg ml À1 ascorbate phosphate and 10 mM b-glycerophosphate (all from Sigma-Aldrich Corp.) for 2 weeks and mineralized deposits were revealed by von Kossa staining (Sigma-Aldrich Corp.). For adipocytes induction, BM-hMSCs were cultured with 10 À7 M dexamethasone, 50 mg ml À1 ascorbate phosphate and 50 mg ml À1 indomethacin for 2 weeks and Oil Red-O (Sigma-Aldrich Corp.) staining was carried out to detect oil-laden cells.
Cell culture dGli36 cells (also known as Gli36qEGFR; kind gift of Dr Ichikawa T and Dr Chiocca EA, The Ohio State University Medical Centre), which overexpresses a truncated mutant epidermal growth factor receptor commonly found in human gliomas were cultured in DMEM supplemented with 10% FBS (Hyclone Laboratories, Logan, UT), 100 U ml À1 penicillin (Invitrogen), 100 mg ml À1 streptomycin (Invitrogen) and 2 mM L-glutamine (Invitrogen), in the presence of 1 mg ml À1 of puromycin (Sigma-Aldrich Corp.). The African green monkey kidney 2-2 cells, which are VERO-derived cells that constitutively express the HSV-1 ICP27 proteins (kindly provided by Dr R Sandri-Goldin, UCLA), 41 were cultivated in the presence of 500 mg ml À1 of geniticin (Sigma-Aldrich Corp.). Normal human astrocytes (NHAs), purchased from Cambrex Bio Science Walkersville Inc, (Walkersville, MD) were cultured in Astrocyte Basal Medium supplemented with recombinant human EGF, insulin, ascorbic acid, GA-100, L-glutamine and FBS as recommended by the supplier (Cambrex Bio Science Walkersville Inc). All cells were maintained at 37 1C in a humidified incubator with 5% CO 2 .
Packaging of helper virus-free HSV-1 amplicon viral vectors and transduction of BM-hMSCs HSV-1 amplicon viral vectors are packaged from a cotransfection of HSV-1 amplicon plasmid in the presence of HSV-1 helper functions provided by a bacterial artificial chromosome that contains the entire HSV-1 genome (fHSVDpacD27 0 þ ) as described previously. 42 pHGCX (HSV-1 amplicon) vector was obtained from Dr Y Saeki (Massachusetts General Hospital, Boston, MA). Following three cycles of freeze-thaw and sonication, the crude viral lysate harvested were filtered through 0.45 mm sterile filter (Millipore, Billerica, MA). The filtered supernatant (14 ml) was added to precleaned ultraclear tubes (30 ml; Beckman Coulter, Fullerton, CA) and overlaid carefully onto a 25% sucrose gradient. This was followed by ultracentrifugation at 25 000 r.p.m. at 4 1C for 4 h with a Beckman SW28 swing-out rotor. After completion of centrifugation, the virus pellets obtained were resuspended in Hank's balanced salt solution (HBSS; 1:100 of original volume) on a platform shaker at 4 1C overnight. The following day, the viruses were gently pipetted up and down a few times, a small aliquot of each fraction was used for titering on 2-2 cells and the remainder was briefly spun to remove the debris prior for storing at À80 1C. For transduction of target cells, pHGCX vector was added to BM-hMSCs (4 Â 10 4 ) seeded in a 24-well dish. After 18 h, viral supernatant were removed and 1 ml fresh medium was added to each well. The efficiency of transduction was assessed by flow cytometry.
Immunofluorescence and immunocytochemistry staining Slides were visualized using wide-field microscopy using an upright microscope (BX51; Olympus, Japan), and images were acquired on a CCD color digital camera (DP11; Olympus). To count the percentage of gene transfer, cells cultured on 24-well dish were visualized using wide-field microscopy with an inverted microscope (TE300; Nikon, Japan), and images were acquired on a CCD color digital camera (DXM1200F) using image acquisition software (ACT-1 v2.7; Nikon). The following antibodies were used for the various staining: CD13, CD34, CD44, CD45, CD49a, CD 90 and CD105 (BD Biosciences, San Jose, CA).
For immunocytochemistry staining, following incubation with primary antibodies, cells were stained with horseradish peroxidase-conjugated anti-mouse polymer, followed by detection using 3,3 0 -diaminobenzidine substrate solution (EnVision þ System; Dako, Glostrup, Denmark). Parallel samples were incubated with match isotype antibodies as specificity control.
Flow cytometry analysis
For flow cytometry analysis, cells were detached using 0.25% trypsin, followed by neutralization with FBS. Cells (1 Â 10 5 ) were resuspended in 500 ml of fluorescenceactivated cell sorting (FACS) buffer (PBS with 5.6% FBS and 5.6% human serum and 0.01 sodium azide) and analyzed by FACS (FACScan, BD Biosciences; quantification with CellQuest software).
Labeling of cells with CM-DiI
Cells (1 Â 10 6 per ml) were incubated with CM-DiI (Invitrogen) red fluorescent label overnight at 37 1C at final concentration of 1 mM. Excess staining reagent was removed the next day and the cells were cultured in dye-free medium for 4 h before used.
In vitro migration assay For determining the in vitro migratory potential of BMhMSCs, BM-hMSCs (2 Â 10 4 ) were cultured in a 24-well tissue culture insert with a filter membrane of 8 mm pore size. Conditioned medium from dGli36 human glioma cells and NHA were added to the bottom well. After 8 h, the filter membrane was fixed with 4% paraformaldehyde and cells were mounted in mounting medium containing 4'6-diamidino-2-phenyl indole (DAPI). Migration of BM-hMSCs was determined by counting the number of DAPI-stained nuclei on the underside of the membrane under Â 200 magnification. Soft agar colony assays Soft agar colony assays were performed by resuspending cells in 1 ml of 1 Â Iscove's modified Dulbecco's medium (Invitrogen) containing 10% FBS and 0.3%. Noble agar (Sigma-Aldrich Corp.). The cell suspension was then layered over 2 ml of 0.6% bottom agar in 35-mm-diameter dishes. After 25 days of incubation at 37 1C, 5% CO 2 incubator, photomicrograph of the colony formation was acquired using a CCD color digital camera (DXM1200F), using image acquisition software (ACT-1 v2.7; Nikon). The experiments were performed in triplicate dishes and at three different cell seeding density of 5 Â 10 3 cells, 5 Â 10 4 and 1 Â 10 5 to ensure consistency.
In vivo migration assay
Cell-cycle analysis
For analyzing the cell-cycle profile, naı¨ve and HSV-1 amplicon viral vector-transduced BM-hMSCs were fixed in 70% ethanol. Following which, cells were resuspended in PBS-containing RNase A (2 mg ml
À1
; Sigma-Aldrich Corp.) and propidium iodide (100 mg ml
; Sigma-Aldrich Corp.). The triplicate samples were stained for 1 h at 4 1C before FACS analysis was performed using CellQuest (BD Biosciences).
Karyotyping
Karyotyping was performed by the Cytogenetics Laboratory of Singapore General Hospital.
Statistical. analysis
Statistical analysis was performed using Prism 3.0 (Graphpad Software Inc, San Diego, CA). Nonpaired parametric data were compared with Student's t-test. P-value o0.05 was considered statistically significant.
Results
Biological characterization of the purified BM-hMSCs BM-hMSCs, isolated from femoral head, were characterized for their cell-surface expression of reported, well-established MSCs-specific markers. 43 The majority of the cells attained the spindle morphology, with low percentage of cells exhibiting polygonal shape (Figure 1a) , and these cells expressed CD13, CD44, CD90 and CD105, and are negative for CD34, CD45 and CD49a (Figure 1b) . Approximately 89.89% of cells were positive for the BM-hMSCs-specific CD90 and CD105 whereas 97.33% of cells stained positive for CD44 (Figure 1b) .
Ability of HSV-1 amplicon viral vector to transduce BM-hMSCs
We have employed the HSV-1 amplicon plasmid, pHGCX, which contains the gene encoding for the enhanced green fluorescent protein (eGFP) under the control of the viral immediate early promoter (IE4/5), as described in Materials and methods section, to test its ability to transduced BM-hMSCs (Figure 2a) . The multiple cloning sites downstream of the cytomegalovirus promoter allow the insertion of transgenes. To study the efficiency of gene transduction mediated by pHGCX, we employed flow cytometry for our analysis. Approximately 41.31±2.12% of eGFP þ cells were detected in pHGCXtransduced BM-hMSCs at MOI of 1.0 (Figure 2bi ). These data strongly suggested that BM-hMSCs are easily infected by the pHGCX HSV-1 amplicon viral vector.
The long-term gene expression of the eGFP reporter gene mediated by the HSV-1 amplicon viral vector was determine by analyzing the percentage of eGFP þ cells at different intervals at 14-day timepoint. The percentage of eGFP þ cells in HSV-1 amplicon viral vector-transduced BM-hMSCs peak on day 1 (43.5±4.7%), and slowly declined over the course of 2 weeks. The percentage of eGFP þ cells decreased to 1.4 ± 0.53% at the end of 2 weeks (Figure 2b(ii) ). These data suggest that the inability of the HSV-1 amplicon viral vector to integrate into the host genome would have affected the stability of gene expression. However, the incorporation of additional elements that are known to confer long-term transgene expression can be incorporated into the HSV-1 amplicon vector backbone to prolong the transgene expression (see Discussion section).
Viral infection has been shown to modulate the proliferation of transduced cells through prolonging the G 0 /G 1 phase, 44 as such we sought to determine whether 
Transduction with pHGCX did not result in the transformation of BM-hMSCs
Karyotype analysis was performed on the BM-hMSCs following gene transduction with the pHGCX HSV-1 amplicon viral vector. The total chromosome number detected was 46 per cells, which was identical to the karyotype of the naı¨ve BM-hMSCs (Figure 3a) . To further rule out the presence of gene modification in the pHGCX-transduced BM-hMSCs, we performed in vitro soft agar transformation assay using pHGCX-transduced BM-hMSCs and naı¨ve BM-hMSCs. Similar to naı¨ve BM-hMSCs, colony formation was not detected for the pHGCX-transduced BM-hMSCs after 1 month in culture. In contrast, a positive control using the dGli36 human brain tumor cell line produced colonies (Figure 3b ). These results further demonstrated that pHGCX HSV-1 amplicon viral vector did not induce chromosomal instability and spontaneous transformation in the BM-hMSCs following transduction. 
HSV-1-mediated gene transfer to BM-hMSCs IAW Ho et al
Multilineage differentiation of gene-modified BM-hMSCs One of the advantages of BM-hMSCs is its ability to differentiate into cells of different lineages. We have therefore investigated whether transduction with the pHGCX HSV-1 amplicon viral vector would affect the multilineage potential of the transduced BM-hMSCs. Naı¨ve BM-hMSCs could be induced to differentiate into adipocytes and osteocytes by incubating in specifically defined induction media as described in Materials and methods section. With the adipogenic-induction medium, accumulation of oil droplets in the cells could be observed after 14 days in culture. The presence of oil droplets was further confirmed by Oil Red-O staining ( Figure 4A (i) (a)). Furthermore, the positive von Kossa staining of the differentiated cells and extracellular matrix after 14 days in culture in osteogenic-induction medium demonstrated that the BM-hMSCs could be differentiated into osteocytes ( Figure 4A (i) (b) ). Both stainings were negative for the uninduced naı¨ve BM-hMSCs cells ( Figure 4B (i) (a) and (b)). The multilineage differentiation potential of pHGCX-transduced BM-hMSCs was intact. This was assessed by incubating the pHGCX-transduced BMhMSCs cells in the osteogenic-and adipogenic-induction medium. As demonstrated in Figure 4A (ii) (b), mineral deposits were detected in cells cultured in the osteogenicinduction medium indicating the ability of the pHGCXtransduced BM-hMSCs to be differentiated into osteocytes. Similar to naı¨ve BM-hMSCs, both the von Kossa and Oil Red-O stained were negative for the uninduced pHGCX-transduced BM-hMSCs ( Figure 4B(ii) ). These results thus confirmed that transduction with the pHGCX HSV-1 amplicon viral vector did not induce the spontaneous differentiation of BMhMSCs and more importantly, transduction with the pHGCX HSV-1 amplicon viral vector did not abrogate the multilineage differentiation capacity of BM-hMSCs.
Transduction with pHGCX HSV-1 amplicon viral vector did not alter the tumor tropism of BM-hMSCs BM-hMSCs has been shown to be able to migrate toward the site of tumor formation both in vitro and in vivo. 16, 25 To investigate whether the transduction with pHGCX HSV-1 amplicon viral vector will alter the tumor tropism of BM-hMSCs, in vitro migration chamber assays were performed. In the presence of either conditioned medium from NHAs or medium alone, both the naı¨ve and pHGCX-transduced BM-hMSCs did not migrate toward the underside of the membrane. However, when conditioned medium from dGli36 human glioma cells were present during the culture, both the naı¨ve and pHGCXtransduced BM-hMSCs migrated significantly toward the HSV-1-mediated gene transfer to BM-hMSCs IAW Ho et al direction of the glioma-conditioned medium ( Figure 5 ). The ability to migrate toward the tumor site was similar for both the naı¨ve and the pHGCX-transduced BM-hMSCs, the slight difference observed was not statistically significant (P ¼ 0.101; Figure 5 ). These data demonstrated that transduction with the pHGCX HSV-1 amplicon viral vector has no consequence on the tumor tropism of BM-hMSCs in vitro.
The effect of HSV-1 amplicon viral vector infection on BM-hMSCs tumor tracking potential was also confirmed in vivo. pHGCX-transduced and naı¨ve CM-DiI-labeled BM-hMSCs were implanted contralaterally to preestablished intracranial dGli36 human glioma cells in nude mice (n ¼ 5). Details of the injection were illustrated in Figure 6a . The eGFP þ pHGCX HSV-1 amplicon viral vector was used as nonmigrating controls. At 2 weeks after the implantation of the naı¨ve or pHGCX-transduced CM-DiI-labeled BM-hMSCs, these cells were detected exclusively at the tumor-bearing hemisphere of the mouse brain (Figure 6b (ii) and (iii)). In contrast, at 2 weeks after 
Discussion
This study is, to the best of our knowledge, the first report to evaluate the use of HSV-1 amplicon viral vector to transduce BM-hMSCs. Our results demonstrated that HSV-1 amplicon viral vector conferred relatively high transduction efficiency without affecting multilineage differentiation, chromosomal stability, tumor tropism and proliferation of transduced BM-hMSCs.
We have shown that BM-hMSCs can be efficiently transduced by HSV-1 amplicon viral vector with a demonstrated transduction efficiency of approximately 41% at MOI of 1.0. These observations are consistent for five different isolates of BM-hMSCs tested. The HSV-1 amplicon vector genome is maintained as episomal elements, which could be an advantage for stem cells therapy. The nonintegrating character of the HSV-1 amplicon vector precludes concerns arising from genetic modifications of the host cells through insertional mutagenesis to result in spontaneous differentiation, transformation, senescence and loss of multilineage differentiation potential. 45 Indeed, our results showed that HSV-1 amplicon viral vector infection did not alter the pluripotent nature of BM-hMSCs (Figure 4) , did not induce the transformation (Figure 3 ) and the spontaneous differentiation of the infected cells (Figure 4) , and did not result in transduction-related toxicity (data not shown). Our in vivo migration results further demonstrated that pHGCX-transduced BM-hMSCs still retained the ability to migrate to the site of tumors after 3 weeks (Figure 6b(iii) ). The transient nature of the gene expression mediated by HSV-1 amplicon viral vectors may be an added advantage in situations where therapeutic gene expression were only required for short period of time.
The issue of safety, especially in vivo, is critical to the success of gene therapy. HSV-1 amplicon viral vectors have been shown to be noncytotoxic and nonimmunogenic. Carlezon et al. 46 and Olschowka et al. 35 showed that both recombinant HSV-1 vectors and HSV-1 amplicon vectors do not elicit cytotoxic effect and immune response when inoculated stereotaxically into rodent brains. In agreement with these observations, we have previously reported that the hepatic transaminases level of immunocompetent Balb/c mice systemically injected with HSV-1 amplicon viral vectors are similar to those injected with saline. 47 Moreover, we did not detect infiltration of CD11b and CD8 cells in the brain of immunocompetent mice 5 days after HSV-1 amplicon viral vectors inoculation (unpublished results). Collectively, these results confirmed the lack of toxicity and The added ability of the HSV-1 amplicon viral vector to harbor large transgene enables the insertion of multiple transcriptional regulatory elements and multiple therapeutic gene cassettes under different promoters. Regulatory elements, such as the adeno-associated virus (AAV) inverted terminal repeat or the Epstein-Barr virus (EBV) elements, could also be incorporated into the HSV-1 amplicon plasmid backbone to confer long-term transgene retention in the transduced cells. The HSV/AAV hybrid vectors has been shown to specifically integrate into the AAVS1 site of the human chromosome 19 and extend transgene expression for up to 12 months. [48] [49] [50] Long-term retention could also be achieved through the incorporation of the EBV nuclear antigen (EBNA-1) and the origin of DNA replication (oriP). 37 Using HSV/EBV hybrid, transgene expression in 4-week-old mice was observed for over 3 weeks. 37 Interactions between EBNA-1 and oriP and the nuclear matrix chromosomal scaffold allow the plasmid to be stably maintained as extrachromosomal elements. The advantageous of using the HSV/EBV hybrid vector is the lack of plasmid integration and its ability to provide long-term gene expression both in vitro and in vivo. In summary, our results clearly demonstrated that BM-hMSCs could easily be transduced by HSV-1 amplicon viral vectors and these vectors could serve as alternatives to attain gene delivery to BM-hMSCs.
